Clinical trials: Pick Disease of the Brain
Frontotemporal Dementia, Behavioral Variant, Alzheimer Disease
Links Between Self-awareness and Sociocognitive Processes in Neurodegenerative Diseases
This monocentric, non-interventional study (SELFSOC) investigates the relationship between self-awareness and social cognition in patients with behavioral variant frontotemporal dementia (bvFTD) and Alzheimer's disease (AD).
- Trial name
- SELFSOC (NCT07531732)
- Testing
- Computer-based facial expression recognition task, Computerized affective task, UCLA Structured Insight Interview
- Where
- France
- Volunteers
- 34 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Psychiatric Adults Patients
Screening of Niemann-Pick Disease, Type C in a Psychiatric Population
Niemann-Pick disease, Type C is a rare genetic disorder characterized by a failing in intracellular cholesterol transport, inducing an accumulation of sphingolipids in the brain.
- Trial name
- NPCPsy (NCT02841358)
- Testing
- Blood sampling, Biopsy
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Grenoble
Niemann-Pick Type C Disease, GM1 Gangliosidosis
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in…
- Conditions
- Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
- Trial name
- NCT07054515
- Testing
- AZ-3102
- Where
- 39 sites in United States, Argentina and 15 more
- Volunteers
- 147 people
- Sponsor
- Azafaros B.V.
Dementia Alzheimers, Dementia With Lewy Bodies
Dementias and Microbiota Composition: Is Possible to Revert the Dementia Symptoms Reverting the Microbiota Composition?
Dementia is the major cause of disability and dependency among older adults worldwide affecting memory, cognitive abilities and behavior, interfering with one's ability to perform daily lives activities.
- Conditions
- Dementia Alzheimers, Dementia With Lewy Bodies, Parkinson Disease Dementia, Dementia Frontotemporal
- Trial name
- DEM-BIOTA (NCT05943925)
- Testing
- No intervention, Probiotic supplement
- Where
- Spain
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University Rovira i Virgili
Dementia, Alzheimer Disease
Effects of Remote-based Resistance Training on Cardiometabolic Risk Factors, Cognitive Function, and Quality of Life in Adults Living With Alzheimer's Disease and/or Related Dementias
The investigators aim to study the effects of a 24-week remote-based resistance exercise training program on cardiovascular disease risk factors, cognitive function, and quality of life in older adults living with mild cognitive…
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular, Lewy Body Disease
- Trial name
- NCT05004558
- Testing
- Remote-based Resistance Exercise Training
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Drexel University
Frontotemporal Dementia, Alzheimer Disease
Young Onset Dementia - the Difficult Diagnosis and the Stressful Life for the Whole Family
People diagnosed with young onset dementia are today mostly assigned to the same healthcare services as people developing dementia at an older age.
- Trial name
- NCT02055092
- Where
- Norway
- Volunteers
- 250 people
- Sponsor
- Norwegian Centre for Ageing and Health
Primary Progressive Aphasia, Behavioral Variant of Frontotemporal Dementia
Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia
This study is designed to learn more about overall tau burden in the brain of patients with Primary Progressive Aphasia (PPA) and Frontotemporal Dementia.
- Conditions
- Primary Progressive Aphasia, Behavioral Variant of Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant
- Trial name
- SLD3 (NCT02736695)
- Testing
- F-18 AV 1451
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Mayo Clinic
Stroke, Acute, Infarction, Middle Cerebral Artery
Autologous Bone Marrow Stem Cells in Ischemic Stroke.
The aim of the study is to determine the safety and tolerability of an autologous CD34+ subset bone marrow stem cell infusion into the middle cerebral artery in patients who have suffered acute total or partial anterior…
- Trial name
- NCT00535197
- Testing
- Infusion of autologous CD34+ stem cells into middle cerebral artery
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Imperial College London
Dementia-related Psychosis
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label…
- Trial name
- NCT03325556
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 83 sites in United States, Bulgaria and 11 more
- Volunteers
- 392 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Sphingomyelin Lipidosis
A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
The primary objective of this study was to obtain data regarding the safety of olipudase alfa in participants with acid sphingomyelinase deficiency (ASMD) who were exposed to long term treatment with olipudase alfa.
- Trial name
- NCT02004704
- Testing
- GZ402665
- Where
- 9 sites in United States, Belgium and 5 more
- Volunteers
- 25 people
- Sponsor
- Genzyme, a Sanofi Company
Sickle Cell Disease, Thalassemia
Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells
This is a clinical trial of bone marrow transplantation for patients with the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling donor.
- Conditions
- Sickle Cell Disease, Thalassemia, Anemia, Granuloma
- Trial name
- NCT00730314
- Testing
- Hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Children's Hospital Los Angeles
Frontotemporal Dementia, Pick's Disease
Oxytocin and Social Cognition in Frontotemporal Dementia
Investigations into the components of cognition damaged in frontotemporal dementia (FTD) demonstrate that patients with FTD show deficits in facial and verbal expression recognition, lack insight into what others think or might…
- Trial name
- NCT01002300
- Testing
- intranasal oxytocin
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Niemann-Pick Disease, Type C1
Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease
This study is planned to study whether lithium carbonate has protective effect on the brain of Niemann-Pick disease type C1.
- Trial name
- NCT03201627
- Testing
- Lithium Carbonate
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Ischemic Stroke
Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial
Patients presenting to the emergency department with acute ischaemic stroke, who are eligible for standard intravenous tPA therapy within 4.5 hours of stroke onset will be assessed for "dual target" major vessel occlusion and…
- Trial name
- EXTEND-IA (NCT01492725)
- Testing
- Intra-arterial Clot Retrieval with Solitaire device, intravenous tissue plasminogen activator (tPA)
- Where
- 9 sites in Australia, New Zealand
- Volunteers
- 70 people
- Sponsor
- Neuroscience Trials Australia
Frontotemporal Dementia
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.
- Trial name
- NCT04374136
- Testing
- Part 1 Blinded - AL001, Part 2 (OLE Treatment) - AL001
- Where
- 44 sites in United States, Argentina and 14 more
- Volunteers
- 119 people
- Sponsor
- Alector Inc.
Niemann-Pick Disease, Type C
VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease
Due to different study designs, the sponsor separated Part C into a separate registration (NCT04958642), leaving Parts A/B here in NCT02534844.
- Trial name
- NCT02534844
- Testing
- Parts A/B: Adrabetadex
- Where
- 29 sites in United States, Australia and 7 more
- Volunteers
- 56 people
- Sponsor
- Mandos LLC
Cerebral Arteriovenous Malformation
Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent (CHOICE)
The objective of this study is to further establish that SQUID, an alternative liquid embolic agent with specific properties, is a safe and effective alternative in bAVM endovascular treatment strategy available to date.
- Trial name
- CHOICE (NCT03413852)
- Testing
- SQUID non-adhesive liquid embolic agent
- Where
- 19 sites in Belgium, Denmark and 3 more
- Volunteers
- 111 people
- Sponsor
- Embo-Flüssigkeiten A.G.
Niemann-Pick Disease, Type C1
Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)
This research study is being conducted to find out whether Trappsol® Cyclo™, an experimental treatment for people with Niemann Pick disease Type C (NPC-1) is safe at 2 different dose levels and what effects it has on people who…
- Trial name
- NCT02939547
- Testing
- Hydroxypropyl-beta-cyclodextrin
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Cyclo Therapeutics, Inc.
Dementia Frontotemporal
Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia
The purpose of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), immunogenicity, and efficacy of multiple intravenous administrations of the investigational drug NS101…
- Trial name
- NCT07154485
- Testing
- NS101 IV infusion
- Volunteers
- 15 people
- Sponsor
- Hee-Jin Kim
Primary Progressive Nonfluent Aphasia
A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia
This study is a pilot trial evaluating the safety and immunogenicity of AADvac1 in patients with the non-fluent variant of Primary Progressive Aphasia.
- Trial name
- AIDA (NCT03174886)
- Testing
- AADvac1 40 µg, AADvac1 160 µg
- Where
- 3 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Axon Neuroscience SE